<DOC>
	<DOCNO>NCT02023463</DOCNO>
	<brief_summary>This phase I trial study side effect best way give enzalutamide , radiation therapy , hormone therapy treat patient intermediate high-risk prostate cancer . Androgens cause growth prostate cancer cell . Antihormone therapy , enzalutamide , may lessen amount androgen make body . Radiation therapy use high energy x ray kill tumor cell . Giving enzalutamide , radiation therapy , hormone therapy may effective treatment prostate cancer .</brief_summary>
	<brief_title>Enzalutamide , Radiation Therapy Hormone Therapy Treating Patients With Intermediate High-Risk Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : 1 ) To assess safety combination neoadjuvant concurrent enzalutamide luteinizing-hormone-releasing hormone ( LHRH ) agonist radiation therapy . SECONDARY OBJECTIVES : 1 . To determine efficacy combination enzalutamide LHRH agonist radiation therapy use prostate specific antigen ( PSA ) kinetics . 2 . To determine efficacy combination enzalutamide LHRH agonist radiation therapy use PSA nadir . 3 . To describe patient-reported outcome include : Expanded Prostate Cancer Index Composite ( EPIC ) , American Urological Association ( AUA ) Symptom Index , PROstate magnetic resonance ( MR ) Imaging Study ( PROMIS ) Fatigue Scale . OUTLINE : Patients receive enzalutamide orally ( PO ) daily ( QD ) 6 month . Beginning 2 week start enzalutamide , patient receive LHRH agonist therapy goserelin acetate subcutaneously ( SC ) leuprolide acetate intramuscularly ( IM ) SC 6 month ( intermediate risk patient ) 24 month ( high risk patient ) post-radiation therapy . Beginning 8 week start LHRH agonist therapy , patient undergo either intensity modulate radiation therapy ( IMRT ) volumetric arc therapy ( VMAT ) daily five day week 8 week . After completion study treatment , patient follow every 3 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>1 . Prostate adenocarcinoma without distant metastatic disease either Gleason score ≥ 7 , PSA ≥ 10 ng/ml , T2b great disease 2 . Age &gt; 18 3 . Performance Status : ECOG 01 4 . Hematologic ( minimal value ) : Absolute neutrophil count &gt; 1,500/mm3 Hemoglobin &gt; 8.0 g/dl Platelet count &gt; 100,000/mm3 5 . Hepatic function Total bilirubin &lt; Upper limit normal ( ULN ) ( except Gilbert 's disease ) AST ( SGOT ) &lt; 1.5 x ULN ALT ( SGPT ) &lt; 1.5 x ULN 6 . Creatinine &lt; 1.5 x ULN 7 . Men childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . 1 . Patients history seizure , underlie brain injury loss consciousness , transient ischemic attack within past 12 month , cerebral vascular accident , brain metastasis , brain arteriovenous malformation use concomitant medication may lower seizure threshold 2 . History urological surgery procedure predispose GU complication radiation ( determine radiation oncologist ) 3 . History diverticulitis , rectal bleed low GI disease predispose GI complication radiation ( determine radiation oncologist ) 4 . History prior chemotherapy pelvic irradiation , 5 . History prior invasive malignant cancer ( ) within last 5 year except adequately treat control basal cell squamous cell carcinoma skin . 6 . Documented distant metastatic disease . NOTE : pelvic lymphadenopathy NOT exclude . 7 . Prior radical prostatectomy cryosurgery prostate cancer bilateral orchiectomy . 8 . No experimental medication within 30 day study entry 9 . Patients currently take follow medication : CYP2C8 inhibitor ( e.g . Gemfibrozil ) CYP2C8 inducer ( e.g . rifampin ) CYP3A4 inhibitor ( itraconazole ) CYP3A4 inducer ( e.g. , carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , rifapentine )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>